why choose us

First received: October 05, 2023

Clinical Trial: Different Doses of Colchicine on hsCRP

Study Status: Completed

Recruit Status: RECRUITING

Condition: Coronary Artery Disease

Study Type: INTERVENTIONAL


Official Title: The Effects of Different Doses of Colchicine on High-sensitivity C-reactive Protein in Patients After Percutaneous Coronary Intervention

Brief Summary: Colchicine reduced atherothrombotic cardiovascular events in the COLCOT and LoDoCo2 studies.US Food and Drug Administration approved colchicine as the first anti-inflammatory drug for cardiovascular diseases on June, 2023.However, there is a lack of evidence for colchicine in East Asian population with coronary heart disease, and its effectiveness and safety need further exploration.Therefore, this study aims to use different doses of colchicine to treat patients with coronary heart disease after percutaneous…

Read more